|
1
|
Wojciechowska U and Didkowska J: Illness
and deaths from malignant tumors in Poland. National Cancer
Registry, Cancer Centre. Institute for them. Maria Sklodowska -
Curie. ISSN: 0867-8251http://onkologia.org.pl/wp-content/uploads/BIUL2013.pdf.
|
|
2
|
Piastowska-Ciesielska AW, Płuciennik E,
Wójcik-Krowiranda K, Bieńkiewicz A, Bednarek A and Ochędalski T:
Analysis of the expression of angiotensin II type 1 receptor and
VEGF in endometrial adenocarcinoma with different
clinicopathological characteristics. Tumour Biol. 33:767–774. 2012.
View Article : Google Scholar
|
|
3
|
Matysiak ZE, Ochędalski T and
Piastowska-Ciesielska AW: The evaluation of involvement of
angiotensin II, its receptors, and androgen receptor in endometrial
cancer. Gynecol Endocrinol. 31:1–6. 2015. View Article : Google Scholar
|
|
4
|
Rodrigues-Ferreira S, Abdelkarim M,
Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, Pontes
CL, Molina A, Cagnard N, Letourneur F, et al: Angiotensin II
facilitates breast cancer cell migration and metastasis. PloS One.
7:e356672012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deshayes F and Nahmias C: Angiotensin
receptors: A new role in cancer? Trends Endocrinol Metab.
16:293–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shan T, Zhang L, Zhao C, Chen W, Zhang Y
and Li G: Angiotensin-(1–7) and angiotensin II induce the
transdifferentiation of human endometrial epithelial cells in
vitro. Mol Med Rep. 9:2180–2186. 2014.PubMed/NCBI
|
|
7
|
Yin T, Ma X, Zhao L, Cheng K and Wang H:
Angiotensin II promotes NO production, inhibits apoptosis and
enhances adhesion potential of bone marrow-derived endothelial
progenitor cells. Cell Res. 18:792–799. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tokinaga Y, Kimoto Y, Ogawa K, Mizumoto K,
Tange K and Hatano Y: Reduction of adhesion formation by an
angiotensin type 1 receptor antagonist. Langenbecks Arch Surg.
396:127–132. 2011. View Article : Google Scholar
|
|
9
|
Domińska K, Piastowska-Ciesielska AW,
Lachowicz-Ochędalska A and Ochędalski T: Similarities and
differences between effects of angiotensin III and angiotensin II
on human prostate cancer cell migration and proliferation.
Peptides. 37:200–206. 2012. View Article : Google Scholar
|
|
10
|
Piastowska-Ciesielska AW, Domińska K,
Nowakowska M, Gajewska M, Gajos-Michniewicz A and Ochędalski T:
Angiotensin modulates human mammary epithelial cell motility. J
Renin Angiotensin Aldosterone Syst. 15:419–429. 2014. View Article : Google Scholar
|
|
11
|
Zhao Y, Wang H, Li X, Cao M, Lu H, Meng Q,
Pang H, Li H, Nadolny C, Dong X, et al: Ang II-AT1R increases cell
migration through PI3K/AKT and NF-κB pathways in breast cancer. J
Cell Physiol. 229:1855–1862. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao Y, Chen X, Cai L, Yang Y, Sui G and
Fu S: Angiotensin II/angiotensin II type I receptor (AT1R)
signaling promotes MCF-7 breast cancer cells survival via
PI3-kinase/Akt pathway. J Cell Physiol. 225:168–173. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Uemura H, Ishiguro H, Nakaigawa N,
Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A and Kubota Y:
Angiotensin II receptor blocker shows antiproliferative activity in
prostate cancer cells: A possibility of tyrosine kinase inhibitor
of growth factor. Mol Cancer Ther. 2:1139–1147. 2003.PubMed/NCBI
|
|
14
|
De Paepe B, Verstraeten VM, De Potter CR
and Bullock GR: Increased angiotensin II type-2 receptor density in
hyperplasia, DCIS and invasive carcinoma of the breast is
paralleled with increased iNOS expression. Histochem Cell Biol.
117:13–19. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo R, Gu J, Zhang Z, Wang Y and Gu C:
MicroRNA-410 functions as a tumor suppressor by targeting
angiotensin II type 1 receptor in pancreatic cancer. IUBMB life.
67:42–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kinoshita J, Fushida S, Harada S, Yagi Y,
Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M,
et al: Local angiotensin II-generation in human gastric cancer:
Correlation with tumor progression through the activation of
ERk1/2, NF-κB and survivin. Int J Oncol. 34:1573–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mohammad RM, Muqbil I, Lowe L, Yedjou C,
Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, et al:
Broad targeting of resistance to apoptosis in cancer. Semin Cancer
Biol. 35(Suppl): S78–S103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao Y, Chen X, Cai L, Yang Y, Sui G and
Wu J: Angiotensin II suppresses adriamycin-induced apoptosis
through activation of phosphatidylinositol 3-kinase/Akt signaling
in human breast cancer cells. Acta Biochim Biophys Sin (Shanghai).
40:304–310. 2008. View Article : Google Scholar
|
|
19
|
Wolf G and Wenzel UO: Angiotensin II and
cell cycle regulation. Hypertension. 43:693–698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zapiecki K, Manahan KJ, Miller GA and
Geisler JP: Cyclin E is overexpressed by clear cell carcinomas of
the endometrium and is a prognostic indicator of survival. Eur J
Gynaecol Oncol. 36:114–116. 2015.PubMed/NCBI
|
|
21
|
Shevra CR, Ghosh A and Kumar M: Cyclin D1
and KI-67 expression in normal, hyperplastic and neoplastic
endometrium. J Postgrad Med. 61:15–20. 2015. View Article : Google Scholar
|
|
22
|
Okegawa T, Pong RC, Li Y and Hsieh JT: The
role of cell adhesion molecule in cancer progression and its
application in cancer therapy. Acta Biochim Pol. 51:445–457.
2004.PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takeda H, Katagata Y, Hozumi Y and Kondo
S: Effects of angiotensin II receptor signaling during skin wound
healing. Am J Pathol. 165:1653–1662. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sakai H, Matsuura K, Tanaka Y, Honda T,
Nishida T and Inui M: Signaling mechanism underlying the promotion
of keratinocyte migration by angiotensin II. Mol Pharmacol.
87:277–285. 2015. View Article : Google Scholar
|
|
26
|
Liu Y, Tian X, Cui M and Zhao S: Safflower
yellow inhibits angiotensin II-induced adventitial fibroblast
proliferation and migration. J Pharmacol Sci. 126:107–114. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Puddefoot JR, Udeozo UK, Barker S and
Vinson GP: The role of angiotensin II in the regulation of breast
cancer cell adhesion and invasion. Endocr Relat Cancer. 13:895–903.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bokhari AA and Syed V: Inhibition of
transforming growth factor-β (TGF-β) signaling by Scutellaria
baicalensis and Fritillaria cirrhosa extracts in endometrial
cancer. J Cell Biochem. 116:1797–1805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Piestrzeniewicz-Ulanska D, Brys M, Semczuk
A, Rechberger T, Jakowicki JA and Krajewska WM: TGF-β signaling is
disrupted in endometrioid-type endometrial carcinomas. Gynecol
Oncol. 95:173–180. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saad S, Stanners SR, Yong R, Tang O and
Pollock CA: Notch mediated epithelial to mesenchymal transformation
is associated with increased expression of the Snail transcription
factor. Int J Biochem Cell Biol. 42:1115–1122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okazaki M, Fushida S, Harada S, Tsukada T,
Kinoshita J, Oyama K, Tajima H, Ninomiya I, Fujimura T and Ohta T:
The angiotensin II type 1 receptor blocker candesartan suppresses
proliferation and fibrosis in gastric cancer. Cancer Lett.
355:46–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qian YR, Guo Y, Wan HY, Fan L, Feng Y, Ni
L, Xiang Y and Li QY: Angiotensin-converting enzyme 2 attenuates
the metastasis of non-small cell lung cancer through inhibition of
epithelial-mesenchymal transition. Oncol Rep. 29:2408–2414.
2013.PubMed/NCBI
|
|
33
|
Okamoto K, Tajima H, Nakanuma S, Sakai S,
Makino I, Kinoshita J, Hayashi H, Nakamura K, Oyama K, Nakagawara
H, et al: Angiotensin II enhances epithelial-to-mesenchymal
transition through the interaction between activated hepatic
stellate cells and the stromal cell-derived factor-1/CXCR4 axis in
intrahepatic cholangiocarcinoma. Int J Oncol. 41:573–582.
2012.PubMed/NCBI
|
